Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes

Status Not yet recruiting

Clinical Trial Summary

It is well established that CD8 and CD4 T cells reactive against defined islet antigens are associated with initiation and progression of Type 1 Diabetes (T1D). In previous work, we have demonstrated that it is possible to redirect T cells against pathogenic T cells via chimeric peptide/MHC/CD3-zeta receptors in a peptide-specific manner and to prevent, or inhibit diabetes in NOD mice. In this study we intend to extend this approach to T cells of T1D patients. Working hypothesis: Beta cell-reactive CD8 T cells of human T1D patients can be immuno-targeted by their own gene-modified cytotoxic T lymphocytes (CTLs). Aims: Our major aim is to demonstrate, in a set of ex-vivo experiments, such immunotargeting with T cells derived from T1D patients at the Ziv Medical Center. To this end we will stimulate and expand autoreactive CD8 cells in blood samples of T1D patients and target them, ex-vivo, with genetically-reprogrammed CTLs which are present in the same blood samples.

Clinical Trial Description

To obtain proof-of-principle of our approach we have initiated tight collaboration between the Laboratory of Immunology at MIGAL Galilee Research Institute, Kiryat Shmona (MIGAL) and Breinin Center for Type 1 Diabetes and Endocrinology at the Ziv Medical Center in Safed (Ziv). In this study we will first identify carriers of the HLA-A0201 allele among pediatric and young adult T1D patients at Ziv. We will then screen the T cell pool in the peripheral blood samples of these patients for CD8 T cells reactive against any of 3 known HLA-A0201-binding peptides associated with autoreactivity in T1D: Insulin beta chain 10-18, IGRP 265-73 and IGRP 222-230. The influenza virus-derived peptide MP 58-66 will serve as reference. Next we will isolate polyclonal CD8 T cells from blood samples of the same patients, activate and expand them ex-vivo and transfect them via electroporation with in-vitro-transcribed mRNA encoding the respective peptide/MHC/CD3-zeta construct(s). We will then perform co-culture experiments assessing the ability of the mRNA-transfected T cells to kill the autoreactive T cells of the same patient in a peptide-selective manner. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02117518
Study type	Observational
Source	Migal Galilee Research Institute
Contact
Status	Not yet recruiting
Phase	N/A
Start date	May 2014
Completion date	May 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05160142` - Diabetes Inspired Culinary Education	Early Phase 1
Withdrawn	`NCT05035368` - Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes	Phase 2
Completed	`NCT01928329` - A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes	Phase 2
Completed	`NCT02127762` - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy	N/A
Completed	`NCT00999375` - Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF)	Phase 2
Active, not recruiting	`NCT04279613` - A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041	Phase 1
Withdrawn	`NCT01477476` - Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes	Phase 2
Terminated	`NCT01308437` - Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics	Phase 3
Terminated	`NCT01652911` - A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation	Phase 1/Phase 2
Completed	`NCT06242548` - How Type I Diabetes Responds to Different Diets (Normoglucidic or Ketogenic) During Physical Activity at Altitude	N/A
Completed	`NCT00351650` - Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan	N/A
Withdrawn	`NCT00361608` - Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device	N/A
Terminated	`NCT03653533` - Evaluation of the Function "Stop Before Hypoglycemia" on External Insulin Pump	N/A
Completed	`NCT00340639` - Management of Type 1 Diabetes Among Adolescents	N/A
Completed	`NCT02634216` - Effects of Capros in Patients With Type-1 Diabetes	N/A
Completed	`NCT02002130` - The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes	Phase 1
Withdrawn	`NCT01623388` - Epigenetic Modifications of Diabetes Mellitus Type I	N/A
Completed	`NCT02612493` - Obesity and Metabolic Surgery in Patients With Type I Diabetes	N/A
Completed	`NCT01843114` - Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects	N/A
Withdrawn	`NCT01398670` - Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms